Welcome to the autumn edition of European Endocrinology. This edition presents a selection of timely and concise review articles by leading experts, with a focus on diabetes ahead of the EASD congress in Vienna, 15-19 September, where free copies will be available to collect from the literature stand.
We welcome a special report from Chantal Mathieu and Lut Overbergh, which offers an overview of the main components of the successful multinational Framework 7 collaboration, and fellow Editorial Board member Baptist Gallwitz provides a timely overview on the future of combination therapies for the treatment of type 2 diabetes. This edition also includes a number of articles on obesity, widely accepted as a major driver of the epidemic of type 2 diabetes. Other important areas are also covered with updates on both thyroid and pituitary disorders.
Please enjoy the expert content and we welcome any feedback.
Foreword – European Endocrinology. 2014;10(2):97
It is my pleasure to provide a foreword for this issue of European Endocrinology, which coincides with a landmark 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna. This meeting promises to be a comprehensive international update on the pathophysiology and treatments of type 1/2 diabetes and its complications. […]
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?
Type 2 diabetes is a progressive disease, therefore, an escalation of therapy is often needed during the course of this chronic and incurable condition in order to prevent late complications associated with poor metabolic control.
The Story of NAIMIT – A Framework 7 Project on Type 1 Diabetes
Type 1 diabetes (T1D) is a relatively rare disease, but attracts much attention as it is a lifelong disease that mainly starts during childhood, thus condemning children to the daily administration of subcutaneous insulin injections, accompanied with a need for painful finger sticks in order to measure glucose levels and an often restrictive lifestyle. Patient […]
Cardiovascular and Diabetes Risk
Diabetic Macular Oedema
Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema
Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults around the world.1 Despite the significance of this problem, and the rising prevalence of diabetes, notably in emerging Asian countries, such as India and China,2,3 there are few precise contemporary estimates of the worldwide prevalence of DR, particularly severe visionthreatening stages of the […]
Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes
Diabetes imposes a substantial burden on societies worldwide: approximately 25 million individuals in the US have diabetes, of which more than 95 % is type 2.1 Furthermore, its incidence is increasing, a further 79 million adults in the US have pre-diabetes and one in three US adults could have diabetes by 2050.1 In addition, the […]
Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin
Insulin Use – Trends and Barriers Of “theoretically unlimited efficacy”: the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) summarise one advantage of insulin for the treatment of type 2 diabetes (T2D).1 Counterpoint disadvantages, most prominently hypoglycaemia, are diminished with the use of insulin analogues in comparison with human […]
Obesity and Weight Management
Energy Flux and its Role in Obesity and Metabolic Disease
Obesity is a global epidemic and represents a substantial health and economic burden.
What is Causing the Worldwide Rise in Body Weight?
For several decades human body weight has been increasing worldwide to a point where the prevalence of overweight and obese adults and children has been described as epidemic or even pandemic.1–6 The statistics are alarming: in 2005 1.6 billion people worldwide were overweight and 400 million people were obese (one in ten adults).
Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer – An Evolving Paradigm
Thyroid cancer is the most common endocrine malignancy, being responsible for approximately 95 % of endocrine cases and 1.5 % of all cancers.1 Its incidence has increased substantially in recent decades and has been rising by 6.4 % per year over the past 10 years.1 This is due to a combination of an apparent increase […]
The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism
Summary An interesting case of persistent hypercalcaemia of primary hyperparathyroidism (pHPT) resistant to medical management for more than 5 years, who demonstrated a dramatic response to the first dose of denosumab with a significant and persistent drop in her level of calcium, from a baseline of 3 mmol/l to 2.7 mmol/l over a period of […]
Primary Hyperparathyroidism Focused on Molecular Pathogenesis
Primary hyperparathyroidism (PHPT) and cancer-related hypercalcaemia are the most common causes of hypercalcaemia and PHPT is the most common cause of hypercalcaemia in outpatients. An autonomous overproduction of parathyroid hormone (PTH) leading to hypercalcaemia, which is not downregulated by the calcium-sensing receptor, is the pathophysiological basis of the disease.1,2
Cardiovascular Risk in Patients with Subclinical Hypothyroidism
Hypothyroidism is usually a progressive disease that impacts the entirety of bodily functions. As the heart is the main target of thyroid hormone activity, hypothyroidism may precipitate or aggravate heart failure, influencing heart rate and blood pressure (BP) while increasing cardiovascular (CV) stiffness and also cardiomegaly.1,2 Overt hypothyroidism (OH) is therefore associated with heightened CV […]
Impairment of Arterial Compliance in Cushing’s Syndrome
Arterial Stiffness and Cardiovascular Risk Recently, much emphasis has been placed on the role of arterial stiffness in the development of cardiovascular diseases. In fact, increased arterial wall rigidity has been acknowledged as a major independent risk factor for cardiovascular pathologies,1,2 and is frequently correlated to the onset of adverse cardiovascular events.3,4 Representing a physiological […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!